ethyl (E)-3-[5-[4-butoxy-2-(1,3-dioxolan-2-ylmethyl)phenyl]-2-(3-formylphenyl)phenyl]prop-2-enoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (E)-3-[5-[4-butoxy-2-(1,3-dioxolan-2-ylmethyl)phenyl]-2-(3-formylphenyl)phenyl]prop-2-enoate
• 化学式: C₃₂H₃₄O₆
• 分子量: 514.6
• InChiKey: OVSBPGUKAYCSDV-GXDHUFHOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  38
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] GPBP-1 INHIBITION AND ITS THERAPEUTIC USE<br/>[FR] INHIBITION DE GPBP-1 ET SON UTILISATION THÉRAPEUTIQUE
  申请人：FIBROSTATIN S L

  公开号：WO2014006020A1

  公开（公告）日：2014-01-09

  The present invention provides compositions including anti-tumor agents and inhibitors of Goodpasture antigen binding protein, p21, and ABCC7, and their use in treating cancer.

  本发明提供了包括抗肿瘤剂和Goodpasture抗原结合蛋白、p21和ABCC7的抑制剂的组合物，并将其用于治疗癌症。
• GPBP-1 inhibition and its therapeutic use
  申请人：Fibrostatin S.L.

  公开号：US20150320730A1

  公开（公告）日：2015-11-12

  The present invention provides compositions including anti-tumor agents and inhibitors of Goodpasture antigen binding protein, p21, and ABCC7, and their use in treating cancer.

  本发明提供了包括抗肿瘤药物和Goodpasture抗原结合蛋白、p21和ABCC7抑制剂的组合物，并将其用于治疗癌症。
• Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes
  申请人：FibroStatin, S.L.

  公开号：US20150093378A1

  公开（公告）日：2015-04-02

  Disclosed herein are methods for treating type 2 diabetes, limiting development of type 2 diabetes, and treating a pre-diabetic state by administering to a subject in need thereof a GPBP inhibitor. Also disclosed herein are methods for diagnosing a pre-diabetic state and for diagnosing a propensity to develop type 2 diabetes by determining an amount of GPBP in a sample from a subject and comparing to control.
• [EN] GOODPASTURE ANTIGEN BINDING PROTEIN DETECTION AND INHIBITION AND ITS USE IN DIABETES<br/>[FR] DÉTECTION ET INHIBITION DE LA PROTÉINE DE LIAISON À L'ANTIGÈNE DE GOODPASTURE ET SON UTILISATION DANS LA CADRE DU DIABÈTE
  申请人：FIBROSTATIN S L

  公开号：WO2015044352A1

  公开（公告）日：2015-04-02

  Disclosed herein are methods for treating type 2 diabetes, limiting development of type 2 diabetes, and treating a pre-diabetic state by administering to a subject in need thereof a GPBP inhibitor. Also disclosed herein are methods for diagnosing a pre-diabetic state and for diagnosing a propensity to develop type 2 diabetes by determining an amount of GPBP in a sample from a subject and comparing to control.